Retinitis Pigmentosa (Retinitis) - 2018 Pipeline Insights - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The “Retinitis Pigmentosa (Retinitis) - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Retinitis Pigmentosa (Retinitis) development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
ScopeThe report provides a snapshot of the pipeline development for Retinitis Pigmentosa (Retinitis) The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Retinitis Pigmentosa (Retinitis) The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Retinitis Pigmentosa (Retinitis) The report also covers the dormant and discontinued pipeline projects related to Retinitis Pigmentosa (Retinitis) Companies FeaturedAcucela Inc.Allergan PLCAmarantus Bioscience Holdings Inc.Amgen Inc.Applied Genetic Technologies Corp.Asklepios BioPharmaceutical Inc.Astellas Pharma Inc.Caladrius Biosciences Inc.Dompe Farmaceutici SpAGenSight Biologics SAGrupo Ferrer Internacional SAID Pharma Co. Ltd.
Key Topics Covered
1. Report Introduction
2. Retinitis Pigmentosa (Retinitis) Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Retinitis Pigmentosa (Retinitis)
4. Comparative Analysis
5. Products in Clinical Stage 5.1 Drug Name: Company NameProduct DescriptionResearch and DevelopmentProduct Development Activities
6. Products in Pre-Clinical and Discovery Stage 6.1 Drug Name: Company NameProduct DescriptionResearch and DevelopmentProduct Development Activities
7. Therapeutic AssessmentAssessment by Route of AdministrationAssessment by Stage and Route of AdministrationAssessment by Molecule TypeAssessment by Stage and Molecule Type
8. Inactive Products 8.1 Drug Name: Company NameProduct DescriptionResearch and DevelopmentProduct Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nzx4nd/retinitis?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005286/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Optical Disorders Drugs
INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/07/2018 10:28 AM/DISC: 09/07/2018 10:27 AM